First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor

NCT07755397 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC Patients With EGFR Activating Mutation
Adenoid Cystic Carcinoma Metastatic
Adenoid Cystic Carcinoma of the Head and Neck

Interventions

DRUG: JBI-778

Sponsor

Jubilant Therapeutics India Limited